Novartis AG ADR (NVS)vsPrecipio Inc (PRPO)
NVS
Novartis AG ADR
$153.27
+0.77%
HEALTHCARE · Cap: $290.96B
PRPO
Precipio Inc
$22.75
+2.80%
HEALTHCARE · Cap: $40.52M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 219377% more annual revenue ($56.69B vs $25.83M). NVS leads profitability with a 22.5% profit margin vs -3.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PRPO
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$153.27
$60.54 premium
Intrinsic value data unavailable for PRPO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Revenue surging 36.2% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -2.7% — below average capital efficiency
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : PRPO
The strongest argument for PRPO centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 36.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PRPO
The primary concerns for PRPO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while PRPO is a hypergrowth play — different risk/reward profiles.
PRPO carries more volatility with a beta of 1.28 — expect wider price swings.
PRPO is growing revenue faster at 36.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 35/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Precipio Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. The company is headquartered in New Haven, Connecticut.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?